Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Total Non-current Assets
All assets not expected to be converted to cash within one year.
Turn Therapeutics Inc.NASDAQ: TTRX
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets of $7.19M in Q1 FY2026
Q1 FY2026 total non-current assets was $7.19M.
Context
- Total non-current assets amounted to 38.6% of total assets at the end of Q1 FY2026.
- Total non-current assets increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 6.97M USD
- Year-over-year change
- +632.5%
- 2-year CAGR
- +192.9%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.97M | +632.5% |
| FY2024 | 2024-12-31 | 950.97K | +17.2% |
| FY2023 | 2023-12-31 | 811.74K | — |
Total Non-current Assets vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 total non-current assets of $7.19M is the 4th highest of the 9 companies compared; the peer median is $740.88K.
- Total non-current assets amounts to 38.6% of total assets for TTRX, versus a peer median of 1.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $91.17M | -48.5% | -22.5% | 48.9% | |
| Mar 2026 | $90.54M | -1.6% | +21.3% | 33.3% | |
| Mar 2026 | $22.72M | +7152.7% | +269.0% | 76.5% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $7.19M | — | — | 38.6% |
| Mar 2026 | $1.16M | +891.5% | +24.7% | 0.7% | |
| Mar 2026 | $326K | -48.6% | -47.6% | 0.9% | |
IRDOpus Genetics, Inc. | Mar 2026 | $186K | -22.2% | +221.3% | 0.3% |
| Apr 2026 | $173K | -18.0% | -3.1% | 1.2% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding TTRX) | $740.88K | -20.1% | +21.3% | 1.0% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.